Volberding P, Conant M A, Stricker R B, Lewis B J
Am J Med. 1983 Apr;74(4):652-6. doi: 10.1016/0002-9343(83)91023-9.
Kaposi's sarcoma has recently appeared in an aggressive form in young, previously healthy, homosexual men. The disease in these patients corresponds most closely to disseminated Kaposi's sarcoma common in areas of Africa. This and the underlying acquired immune deficiency in the current patients in the United States affect the choice of appropriate therapy. Because Kaposi's sarcoma in these patients is rapidly progressive, it often requires aggressive systemic therapy, but this can be difficult given the patients' susceptibility to opportunistic infections. Reports from Africa suggest that Kaposi's sarcoma is very responsive to several chemotherapeutic agents, but these data must be interpreted cautiously because of problems in study design and differences between cases in Africa and the United States. This report reviews the clinical classification of Kaposi's sarcoma and the reported results of chemotherapy in patients with advanced disease. Implications of this experience in the treatment of recent cases in the United States are discussed.
卡波西肉瘤最近在年轻、既往健康的同性恋男性中以侵袭性形式出现。这些患者所患疾病与非洲地区常见的播散性卡波西肉瘤最为相似。美国当前这些患者的这种疾病以及潜在的获得性免疫缺陷影响了适当治疗方法的选择。由于这些患者的卡波西肉瘤进展迅速，通常需要积极的全身治疗，但鉴于患者易发生机会性感染，这可能会很困难。来自非洲的报告表明，卡波西肉瘤对几种化疗药物反应良好，但由于研究设计存在问题以及非洲和美国病例之间的差异，这些数据必须谨慎解读。本报告回顾了卡波西肉瘤的临床分类以及晚期疾病患者化疗的报告结果。并讨论了这一经验对美国近期病例治疗的启示。
